Dare Bioscience Inc
$ 2.15
-0.92%
26 Dec - close price
- Market Cap 28,980,900 USD
- Current Price $ 2.15
- High / Low $ 2.19 / 2.09
- Stock P/E N/A
- Book Value 0.20
- EPS -1.83
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.45 %
- ROE -25.43 %
- 52 Week High 3.38
- 52 Week Low 1.61
About
Dare Bioscience, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to transforming women's health through the development of innovative therapeutic solutions. With a robust pipeline of products targeting unmet medical needs in diverse areas of women's health, the company is well-positioned for impactful commercialization. By focusing on the distinct healthcare challenges that women face, Dare Bioscience aims to enhance patient outcomes and establish itself as a leader in the evolution of women's healthcare.
Analyst Target Price
$10.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-13 | 2025-08-14 | 2025-05-05 | 2025-03-26 | 2024-11-07 | 2024-08-08 | 2024-05-14 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-30 |
| Reported EPS | -0.28 | -0.45 | -0.5 | -0.65 | -0.55 | -0.88 | -0.07 | -0.06 | -0.09 | -0.1 | -0.09 | -0.19 |
| Estimated EPS | 0.02 | 0.03 | -0.58 | -0.6333 | -0.73 | 0.02 | -0.06 | -0.1 | -0.1 | -0.1 | -0.1 | -0.14 |
| Surprise | -0.3 | -0.48 | 0.08 | -0.0167 | 0.18 | -0.9 | -0.01 | 0.04 | 0.01 | 0 | 0.01 | -0.05 |
| Surprise Percentage | -1500% | -1600% | 13.7931% | -2.637% | 24.6575% | -4500% | -16.6667% | 40% | 10% | 0% | 10% | -35.7143% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DARE
2025-12-22 11:10:34
Dare Bioscience has received additional funding from the National Institute of Allergy and Infectious Diseases (NIAID) for its investigational HPV treatment, DARE-101. This funding, totaling $2.8 million over the next year, supports the ongoing Phase 1/2 clinical trial and preclinical development. DARE-101 is being developed as a non-surgical, topical treatment for high-risk HPV and pre-invasive cervical lesions.
2025-12-11 12:09:46
Daré Bioscience has announced that pre-orders are now open for DARE to PLAY Sildenafil Cream, a topical arousal cream for women designed to enhance genital blood flow and arousal response. This product, containing the active ingredient sildenafil, is available as a Section 503B compounded product in select U.S. states. While not FDA-approved, the formulation has undergone extensive evaluation, and Daré Bioscience is pursuing FDA approval for its proprietary cream.
2025-12-10 23:09:35
Daré Bioscience has made DARE to PLAY sildenafil cream commercially available in select states, offering a non-hormonal topical option to improve genital blood flow and arousal in women. This product, which is not FDA-approved but supported by exploratory randomized trial data, aims to address the long-standing gap in sexual medicine for women. Prescribing access is currently available in a limited number of states, with wider availability anticipated through 2025–2026.
2025-12-10 14:11:28
Dare Bioscience (DARE) has launched prescriptions for its DARE to PLAY Sildenafil Cream, aiming to address a significant gap in female sexual health solutions. While this product is a major advancement for women's health, the company faces financial challenges, including negative revenue growth and a distressed Altman Z-Score, necessitating careful due diligence for investors despite a neutral market sentiment.
2025-12-08 21:10:34
Daré Bioscience announced the commencement of pre-orders by prescription for its DARE to PLAY™ Sildenafil Cream, an evidence-backed topical arousal cream for women, starting December 10, 2025. This product, manufactured in a 503B outsourcing facility and not FDA approved, will initially be available in 10 states. The announcement led to a positive market reaction for DARE stock, which gained 6.99%.
2025-12-02 05:22:20
Dare Bioscience announced the regaining of full rights to its Ovaprene Phase 3 program. This follows ongoing positive interim data and grant funding, positioning the asset for value maximization. The termination, effective February 2026, gives Dare full control over Ovaprene.
